<DOC>
	<DOCNO>NCT02167360</DOCNO>
	<brief_summary>This single arm , open-label , multi-center , phase II study determine efficacy safety CTL019 adult patient r/r B-cell ALL . The study follow sequential phase : Screening , Pre-Treatment , Treatment Primary Follow-up , Secondary Follow-up ( Relapse Follow-up ) Survival Follow-up . The total duration primary follow-up 1 year cell infusion . Safety assess end treatment primary follow-up phase .</brief_summary>
	<brief_title>Study Efficacy Safety CTL019 Adult ALL Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<criteria>Relapsed refractory adult Bcell ALL . First great Bone Marrow ( BM ) relapse OR b . Any BM relapse allogeneic stem cell transplantation ( SCT ) must &gt; 6 month SCT time CTL019 infusion OR c. Refractory define achieve CR ( morphology &lt; 5 % blast ) 2 cycle standard chemotherapy regimen OR d. Patients Philadelphia chromosome positive ( Ph+ ) ALL eligible intolerant fail tyrosine kinase inhibitor therapy ( TKI ) , TKI therapy contraindicate . For relapsed patient , documentation CD19 tumor expression bone marrow peripheral blood flow cytometry within 3 month screen Adequate organ function define : a. Renal function define : . A serum creatinine &lt; 1.5 x ULN OR ii . Calculated creatinine clearance radioisotope Glomerular Filtration Rate ( GFR ) &gt; 60 mL/min/1.73 m2 b. Alanine Aminotransferase ( ALT ) &lt; 5 time upper limit normal ( ULN ) c. Bilirubin &lt; 2.0 mg/dL d. Must minimum level pulmonary reserve define ≤Grade 1 dyspnea pulse oxygenation &gt; 91 % room air e. Left Ventricular Ejection Fraction ( LVEF ) ≥ 45 % confirm echocardiogram Multiple Uptake Gated Acquisition ( MUGA ) Bone marrow ≥ 5 % lymphoblast morphologic assessment screening Age &gt; 18 year A ECOG Performance Status either 0 1 screening Signed write informed consent must obtain prior study procedure Once eligibility criterion confirm , must apheresis product nonmobilized cell receive accepted manufacturing site . Note : Apheresis product assess acceptance manufacturing site document confirmation eligibility criterion . Women childbearing potential ( defined woman physiologically capable become pregnant ) must agree use highly effective method contraception entire study period ( 1 year CTL019 infusion ) . Highly effective contraception method include : 1 . Total abstinence ( line prefer usual lifestyle patient . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal NOT acceptable method contraception ) 2 . Female sterilization ( surgical bilateral oophorectomy without hysterectomy ) tubal ligation least six week take study treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment 3 . Male sterilization ( least 6 month prior screen ) . For female patient study vasectomized male partner sole partner patient 4 . BOTH follow form contraception must utilize : Use oral , injected implant hormonal method contraception form hormonal contraception comparable efficacy ( failure rate &lt; 1 % ) , example hormone vaginal ring transdermal hormone contraception Barrier method contraception : Condom Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/vaginal suppository 5 . Use intrauterine device ( IUD ) exclude due increase risk infection bleed population 6 . In case use oral contraception , woman must stable pill minimum 3 month take study treatment Women reproductive potential ( define postmenopausal least 24 consecutive month ( i.e . menses ) undergo hysterectomy , salpingotomy , and/or bilateral oophorectomy ) eligible without require use contraception . Acceptable documentation include write oral documentation communicate clinician clinician 's staff one following : 1 . Physician report/letter 2 . Operative report source documentation patient record 3 . Discharge summary 4 . Follicle stimulate hormone measurement elevate menopausal range . Isolated extramedullary disease relapse Patients concomitant genetic syndrome Fanconi anemia , Kostmann syndrome , Shwachman syndrome know bone marrow failure syndrome . Patients Burkitt 's lymphoma/leukemia ( i.e . patient mature Bcell ALL , leukemia Bcell [ surface Immunoglobulin ( sIg ) positive kappa lambda restrict positivity ] ALL , French , American , British [ FAB ] L3 morphology /or MYC translocation ) Prior malignancy , unless treat curative intent evidence active disease present &gt; 5 year screen Treatment prior gene therapy product Has treatment prior antiCD19/antiCD3 therapy , antiCD19 therapy Active latent hepatitis B active hepatitis C , uncontrolled infection screen 8 . Human Immunodeficiency Virus ( HIV ) infection screen 9 . Presence grade 2 4 acute extensive chronic graftversushost disease ( GVHD ) 10 . The following medication exclude : a. Steroids : Therapeutic dos steroid must stop &gt; 72 hour prior CTL019 infusion . However , follow physiological replacement dos steroid allow : &lt; 612 mg/m2/day hydrocortisone equivalent . Topical steroid permit . b. Allogeneic cellular therapy : Any donor lymphocyte infusion ( DLI ) must complete &gt; 6 week prior CTL019 infusion c. GVHD therapy : Any drug use GVHD must stop &gt; 4 week prior CTL019 infusion ( e.g . calcineurin inhibitor , methotrexate chemotherapy drug , mycophenolyate , University Pennsylvania Page 20 138 Oncology Protocol Protocol No . UPCC # 07414/CCTL019B2207J V00.1 04022014 steroid [ see ] , rapamycin , thalidomide , immunosuppressive antibody rituximab , antitumor necrosis factor [ antiTNF ] , antiinterleukin 6 [ antiIL6 ] antiinterleukin 6 receptor [ antiIL6R ] ) d. Chemotherapy : . The following drug must stop &gt; 1 week prior CTL019 infusion : hydroxyurea , vincristine , 6mercaptopurine , 6thioguanine , methotrexate &lt; 25 mg/m2 , cytosine arabinoside &lt; 10 mg/m2/day , asparaginase ii . The following drug must stop &gt; 4 week prior CTL019 infusion : salvage chemotherapy ( e.g . clofarabine , cytosine arabinoside &gt; 100mg/m2 , anthracyclines , cyclophosphamide ) , exclude require lymphodepleting chemotherapy drug e. CNS disease prophylaxis i. CNS prophylaxis treatment must stop &gt; 1 week prior CTL019 infusion ( e.g . intrathecal methotrexate ) . 11 . Active Central Nervous System ( CNS ) involvement malignancy , define CNS3 per National Comprehensive Cancer Network ( NCCN ) guideline . Note : Patients history CNS disease effectively treat eligible . 12 . Patient receive investigational medicinal product within last 30 day prior screen 13 . Pregnant nursing ( lactate ) woman . NOTE : female study participant reproductive potential must negative serum urine pregnancy test perform within 48 hour infusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>adult patient</keyword>
	<keyword>B-cell ALL</keyword>
	<keyword>chemo-refractory</keyword>
	<keyword>relapse allogeneic SCT</keyword>
	<keyword>ineligible allogeneic SCT</keyword>
</DOC>